Evaluation of epothilone B analog in advanced soft tissue sarcoma: A phase II study of the phase II consortium

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 3069-3073

  Okuno, Scott ^a   Maples, William J ^a   Mahoney, Michelle R ^a   Fitch, Tom ^a   Stewart, James ^a   Fracasso, Paula M ^a   Kraut, Michael ^a   Ettinger, David S ^a   Dawkins, Fitzroy ^a   Erlichman, Charles ^a  

^a Mayo Clinic

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; EPOTHILONE B; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IXABEPILONE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; ILEUM DISEASE; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SENSORY DYSFUNCTION; SOFT TISSUE SARCOMA; SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SARCOMA; TREATMENT OUTCOME;

EID: 21144441199     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.372     Document Type: Article

References (21)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics 2004. CA Cancer J Clin 54:8-29, 2004
2. Brennan MR, Alextiar KM, Maki RG: Sarcomas of the Soft Tissue and Bones, in DeVita V, Hellman S, Rosenber SA (eds): Cancer Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 2001, pp 1841-1883
3. Gerth K, Bedorf N, Hofle G, et al: Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium celulosom (Myxobacteria): Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49:560-563, 1996
4. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agent with a Taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
5. Goodin S, Kane MP, Rubin EH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025, 2004
6. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
7. Fleming TR: One sample multiple testing procedures for phase II clinical trials. Biometrics 43:143-151, 1982
8. Duffy DE, Santner TJ: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93, 1987
9. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
10. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 74:187-220, 1972
11. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin, or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcoma. J Clin Oncol 11:1269-1275, 1993
12. Demetri GD, vonMehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
13. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002
14. Casper ES, Waltzman RJ, Schwartz GK, et al: Phase II trial of paclitaxel in patients with soft-tissue sarcomas. Cancer Invest 16:442-446, 1998
15. Edmonson JH, Ebbert LP, Nasciment AG, et al: Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 19:574-576, 1996
16. Gill PS, Tulpule A, Espina BM, et al: Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 17:1876-1883, 1999
17. Okuno SH, Edomson JH, Mahoney M, et al: Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225-3229, 2002
18. Okuno SH, Ryan LM, Edmonson JH, et al: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). Cancer 97:1669-1673, 2003
19. Patel SR, Gandhi V, Jenkins J, et al: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001
20. Hensley ML, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824-2831, 2002
21. Leu K, Ostuszka LJ, Biermann JS, et al: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of osteosarcoma. Proc Am Soc Clin Oncol 22:816, 2003 (abstr 3278)